|
🐜
|
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
14 auth.
M. Dougados,
D. M. van der Heijde,
Ying-Chou Chen,
M. Greenwald,
E. Drescher,
Jiajun Liu,
S. Beattie,
S. Witt,
I. de la Torre,
C. Gaich,
...
Terence Rooney,
D. Schlichting,
S. de Bono,
P. Emery
|
8 |
2016 |
8
🐜
|
|
🐜
|
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
9 auth.
D. M. van der Heijde,
A. Deodhar,
J. Wei,
E. Drescher,
D. Fleishaker,
T. Hendrikx,
...
David Li,
S. Menon,
K. Kanik
|
8 |
2016 |
8
🐜
|
|
🐜
|
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
12 auth.
E. Keystone,
P. Taylor,
E. Drescher,
D. Schlichting,
S. Beattie,
P. Berclaz,
...
Chin H Lee,
Rosanne Fidelus-Gort,
M. Luchi,
Terence Rooney,
W. Macias,
M. Genovese
|
8 |
2014 |
8
🐜
|
|
🐜
|
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and
91 auth.
D. Heijde,
J. Wei,
M. Dougados,
P. Mease,
A. Deodhar,
W. Maksymowych,
F. Bosch,
J. Sieper,
T. Tomita,
R. Landewé,
F. Zhao,
E. Krishnan,
D. Adams,
B. Pangallo,
H. Carlier,
...
M. Churchill,
K. Flint,
G. Gladstein,
M. Greenwald,
Mary Howell,
A. Ince,
J. Kaine,
D. Mehta,
Eric Peters,
R. Querubin,
J. Reveille,
Richard Roseff,
R. Diegel,
Christine Thai,
L. Bessette,
F. Morin,
P. Rahman,
Aa Rodriguez,
F. Cons-Molina,
S. Barragan,
Cassandra C. Skinner,
C. P. Tena,
César Ramos Remus,
J. Rodriguez,
Seung-Jae Hong,
Yeon-Ah Lee,
J. Ju,
S. Kang,
Tae-Hwan Kim,
C. Lee,
E. Lee,
Sang Heon Lee,
Min-Chan Park,
K. Shin,
Sang-Hoon Lee,
Hung-An Chen,
Ying-Chou Chen,
S. Hsieh,
J. Lan,
Z. Dvořák,
R. Moravcová,
Martina Malcova,
Y. Taniguchi,
M. Kishimoto,
K. Tada,
H. Dobashi,
K. Inui,
Y. Ueki,
Y. Matsumoto,
Y. Koyama,
K. Hatta,
T. Atsumi,
H. Goto,
K. Matsui,
Y. Takakubo,
G. Neeck,
D. Poddubnyy,
A. Rubbert-Roth,
M. Szymańska,
T. Blicharski,
A. Dudek,
A. Racewicz,
R. Wojciechowski,
M. V. D. Sande,
E. Griep,
M. Nurmohamed,
G. Matsievskaya,
E. Shmidt,
M. Stanislav,
S. Yakushin,
O. Ershova,
A. Rebrov,
T. Balazs,
R. Cseuz,
E. Drescher,
G. Poór
|
7 |
2018 |
7
🐜
|
|
🐜
|
The Efficacy and Safety of Clazakizumab, an Anti–Interleukin‐6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
7 auth.
P. Mease,
A. Gottlieb,
A. Berman,
E. Drescher,
J. Xing,
R. Wong,
...
Subhashish Banerjee
|
7 |
2016 |
7
🐜
|
|
🐜
|
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study
10 auth.
M. Weinblatt,
P. Mease,
E. Mysler,
T. Takeuchi,
E. Drescher,
A. Berman,
...
J. Xing,
M. Zilberstein,
Subhashish Banerjee,
P. Emery
|
6 |
2015 |
6
🐜
|
|
🐜
|
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
11 auth.
P. Tak,
A. Balanescu,
V. Tseluyko,
S. Bojin,
E. Drescher,
D. Dairaghi,
...
S. Miao,
V. Marchesin,
J. Jaén,
T. Schall,
P. Bekker
|
6 |
2012 |
6
🐜
|
|
🐜
|
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.
10 auth.
J. Tuttle,
E. Drescher,
J. Simón-Campos,
P. Emery,
M. Greenwald,
A. Kivitz,
...
H. Rha,
Pia Yachi,
Christina Kiley,
A. Nirula
|
5 |
2023 |
5
🐜
|
|
🐜
|
LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study
12 auth.
M. Dougados,
D. Heijde,
Y. Chen,
M. Greenwald,
E. Drescher,
Jiajun Liu,
...
S. Beattie,
I. Torre,
Terence Rooney,
D. Schlichting,
S. Bono,
P. Emery
|
4 |
2015 |
4
🐜
|
|
🐜
|
OP0258 IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS FROM A PHASE 2 STUDY
10 auth.
F. Behrens,
P. Taylor,
D. Wetzel,
N. Brun,
J. Brandt-Juergens,
E. Drescher,
...
E. Dokoupilova,
A. Rowińska-Osuch,
N. Abdel-Kader Martin,
K. de Vlam
|
4 |
2022 |
4
🐜
|
